blood test

Octave Bioscience is entering into a collaboration with Quest Diagnostics to expand access to its multiple sclerosis disease activity (MSDA) test, which uses data from a set of blood biomarkers to measure how active a patient’s disease is in people with multiple sclerosis (MS). Although the MSDA…

A new grant from the Valhalla Foundation will help Octave Bioscience advance the development of a biomarker blood test for detecting disease progression in people with multiple sclerosis (MS). The company is developing its MS Disease Progression test, or MSDP, to objectively measure MS progression based on…

Octave Bioscience has raised $35.6 million in funding to continue marketing its multiple sclerosis (MS) disease activity test and accelerate the development of a similar tool for Parkinson’s disease. The Multiple Sclerosis Disease Activity (MSDA) test — the first blood test of its kind…

Researchers have developed a blood test to identify people at risk of developing multiple sclerosis (MS) years before the first symptoms appear. The test, described in a recent study, looks for antibodies against a protein of the Epstein-Barr virus (EBV), which is a leading risk factor for MS.

Octave Bioscience’s Multiple Sclerosis Disease Activity (MSDA) test, which uses data from blood biomarkers to assess multiple sclerosis (MS) disease activity, is now available across all 50 U.S. states to help guide clinicians’ decisions about care. Octave said the test received certification from the New York State Clinical…

Siemens Healthineers has received the CE mark in Europe for a lab-based blood test that measures the levels of neurofilament light chain, known as NfL — a protein that gets released into the bloodstream upon damage to nerve cells — in adults with relapsing forms of multiple sclerosis…

Measuring the amount of specific antibody clumps in the blood helped distinguish people with multiple sclerosis (MS) from healthy individuals and people with other conditions with an accuracy of at least 90%, a new study has found. The findings show that clumps of immunoglobulin G (IgG) antibodies — which…

Labcorp has launched a widely accessible test that measures the levels of neurofilament light chain (NfL), a biomarker of nerve damage, to screen for signs of neurodegenerative diseases such as multiple sclerosis (MS). The test is performed on a standard blood sample taken at a hospital, at the…

A blood biomarker test developed by Octave can effectively monitor overall disease activity in people with multiple sclerosis (MS), helping to improve the care being given, the company reported. The assay, dubbed the MS Disease Activity (MSDA) test, can also be used to monitor disease activity across…

Siemens Healthineers has signed a license and supply agreement with Quanterix that helps it in developing blood tests for neurofilament light chain (NfL) to aid in early disease detection, evidence of progression, and measuring treatment response in people with neurological disorders such as multiple sclerosis (MS). Siemens Healthineers…

A product called acrolein, which is naturally excreted by the body and possible to measure in urine and blood, may be a potential biomarker to help diagnose and evaluate disease activity in people with multiple sclerosis (MS), according to preliminary research in animal models and humans. Researchers are investigating whether acrolein…

Blood levels of the nerve damage marker neurofilament light provide a reliable picture of multiple sclerosis activity in both the relapsing-remitting and progressive forms of the disease, a Swedish study reports. The University of Gothenburg researchers also discovered a close link between its levels in blood and spinal fluid. This means the…

A blood test may someday replace some of the magnetic resonance imaging (MRI) scans taken by people with multiple sclerosis (MS)  — offering an easy, cheap alternative for monitoring disease activity. A study by Norway’s University of Bergen found that blood levels of a factor called neurofilament light chain, released…

In the future, a blood test may make diagnosing multiple sclerosis (MS) much easier, thanks to newly identified biomarker patterns that distinguish between MS patients and healthy people. The test could also correctly detect primary progressive MS (PPMS) in patients who also had relapsing-remitting disease (RRMS). Australian researchers suggest that…

IQuity Taking Orders for RNA-based Blood Test That Can Detect MS Early with 90% Accuracy Can it be that there’s now a blood test that can help diagnose MS? This company says it has one and doctors can order it. For a disease that’s always been…

The life science tech company IQuity has begun taking orders from physicians for an RNA-based blood test that can provide reliable yes or no results for multiple sclerosis in seven days – dramatically faster than previous options, which took months or years. The test, IsolateMS, can be a game-changer in…

The National Institutes of Health (NIH) has awarded a $1 million grant to IQuity, a Nashville-based company looking into novel RNA targets that ultimately benefit patients with multiple sclerosis (MS) and other autoimmune disorders. The NIH grant is part of the institute’s Small Business Innovation Research (SBIR) program.

Molecular diagnostics startup IQuity is introducing a pioneering blood test that speeds up multiple sclerosis (MS) diagnosis to just seven days. Previously, this process could take up to months or years. IQuity, based in Nashville, Tennessee, began working on its new IsolateMS blood test in January 2016, after receiving $2…

Here’s my Pick of the Week’s News, as published in Multiple Sclerosis News Today. Blood Test Seen to Distinguish MS from Other Neurological Conditions A faster way to tell the difference between neurological diseases could mean earlier access to treatment for MS patients. Researchers at Michigan State…